BioLife Solutions, Inc. (BLFS) financial statements (2021 and earlier)

Company profile

Business Address 3303 MONTE VILLA PARKWAY
BOTHELL, WA 98021
State of Incorp. DE
Fiscal Year End December 31
SIC 3845 - Electromedical and Electrotherapeutic Apparatus (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
3/31/2018
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments2120323132147
Cash and cash equivalents2120323132147
Receivables4433321
Inventory, net of allowances, customer advances and progress billings6544322
Inventory6544322
Other undisclosed current assets1000000
Total current assets:32293938381910
Noncurrent Assets
Operating lease, right-of-use asset111
Property, plant and equipment2111111
Long-term investments and receivables1667721
Long-term investments1667721
Intangible assets, net (including goodwill)4514     
Goodwill2810     
Intangible assets, net (excluding goodwill)164     
Deposits noncurrent assets0000000
Other undisclosed noncurrent assets3      
Total noncurrent assets:522398832
TOTAL ASSETS:84524845462212
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities4222221
Accounts payable2111111
Accrued liabilities1000000
Employee-related liabilities2111110
Debt111    
Deferred rent credit   0000
Business combination, contingent consideration, liability00     
Total current liabilities:5332221
Noncurrent Liabilities
Long-term debt and lease obligation111    
Finance lease, liability000
Operating lease, liability111
Liabilities, other than long-term debt2200001
Deferred rent credit   0000
Other liabilities0000000
Business combination, contingent consideration, liability22     
Total noncurrent liabilities:2210001
Total liabilities:7542322
Stockholders' equity
Stockholders' equity attributable to parent77464443442010
Preferred stock    000
Common stock0000000
Additional paid in capital1371161151141169385
Accumulated deficit(60)(70)(71)(71)(72)(73)(74)
Total stockholders' equity:77464443442010
TOTAL LIABILITIES AND EQUITY:84524845462212

Income statement (P&L) ($ in millions)

9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
3/31/2018
Q1
Revenues7765554
Cost of revenue
(Cost of Goods and Services Sold)
(2)(2)(2)(2)(2)(2)(1)
Gross profit:5544442
Operating expenses(5)(4)(4)(3)(2)(2)(2)
Operating income (loss):(1)101110
Nonoperating income (expense)10(0)(0)(0)0(0)(0)
Interest and debt expense(0)(0)(0)(0)(0)(0)(0)
Income from continuing operations before equity method investments, income taxes:9101110
Loss from equity method investments   (1)   
Other undisclosed income from continuing operations before income taxes00 100 
Net income:9101110
Other undisclosed net income attributable to parent  0   0
Net income attributable to parent:9101110
Preferred stock dividends and other adjustments   (0)(0)(0)(0)
Net income (loss) available to common stockholders, diluted:910111(0)

Comprehensive Income ($ in millions)

9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
3/31/2018
Q1
Net income:9101110
Comprehensive income, net of tax, attributable to parent:9101110

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: